Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Summit Therapeutics plc (NASDAQ: SMMT).

Full DD Report for SMMT

You must become a subscriber to view this report.


Recent News from (NASDAQ: SMMT)

The Market Has Spoken: Buy Sarepta
May the Fourth, 2018 May 4th is a special day for Star Wars fans, because it sounds like 'may the force' (as in 'May the force be with you'). It would seem that May 4th, 2018 perhaps will go down in memory as a special day not only for Star Wars fans, but for Sarepta Therapeutic ( SRPT ) i...
Source: SeekingAlpha
Date: May, 07 2018 11:32
Solid Biosciences moving closer to removal of clinical hold on early-stage study of DMD candidate SGT-001; shares up 6%
Thinly traded Solid Biosciences ( SLDB +5.5% ) is up, albeit on turnover of only 85K shares, on its announcement that it has received a letter from FDA concerning the full clinical hold on its Phase 1/2 study of gene therapy SGT-001 in patients with Duchenne muscular dystrophy. The agenc...
Source: SeekingAlpha
Date: April, 30 2018 13:43
Capricor launches mid-stage study of DMD candidate CAP-1002; shares up 2%
Capricor Therapeutics ( CAPR +1.5% ) initiates a Phase 2 clinical trial, HOPE-2 , assessing CAP-1002 in boys and young men with Duchenne muscular dystrophy (DMD). More news on: Capricor Therapeutics, Inc., Sarepta Therapeutics, Inc., Catabasis Pharmaceuticals, Healthcare stocks news, ...
Source: SeekingAlpha
Date: April, 30 2018 13:23
3 Things In Biotech, April 23: Support, Support, And Those Blasted Blood Vessels
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: April, 24 2018 08:00
Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late-Breaking Presentation at ECCMID 2018
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces it highlighted the discovery of new mechanism antibiotic candidates for the treatment of gonorrhoea in a late-breaking presentation at the 28th Eur...
Source: GlobeNewswire
Date: April, 23 2018 07:00
Award of Share Options and Restricted Stock Units
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), announces that the following options over new ordinary shares of one penny nominal value (‘Ordinary Shares’) were granted on 20 April 2018 to the C...
Source: GlobeNewswire
Date: April, 23 2018 06:45
Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting
Data show correlation between decreases in muscle damage and reduction in muscle inflammation in patients treated with ezutromid OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces the pres...
Source: GlobeNewswire
Date: April, 20 2018 07:00
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
OXFORD, United Kingdom and CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces the completion of ezutromid dosing in patients with Duchenne muscular dystrophy (‘DMD’) for the full 48-week PhaseOut DMD clinical trial. ...
Source: GlobeNewswire
Date: April, 19 2018 07:00
Summit Therapeutics 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Summit Therapeutics in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: April, 12 2018 12:53
Dosing underway in early-stage study of Pfizer's DMD candidate
The first patient has been dosed in a Phase 1b clinical trial assessing Pfizer's (NYSE: PFE ) Duchenne muscular dystrophy (DMD) candidate PF-06939926. More news on: Pfizer Inc., Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 12 2018 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1713.5314.0714.1013.5337,526
2017-02-0311.2510.9511.2510.62510,824
2017-02-0211.4311.2411.7710.47519,357
2017-02-0111.2711.9311.9811.2752,978
2017-01-3110.3010.4710.49810.2316,964

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2117,58930,86256.9924Short
2018-08-2019,28739,24649.1439Short
2018-08-1730,40562,28848.8136Short
2018-08-16413,212800,37651.6272Short
2018-08-1541,54266,15462.7959Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SMMT.


About Summit Therapeutics plc (NASDAQ: SMMT)

Logo for Summit Therapeutics plc (NASDAQ: SMMT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: SMMT)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 15 2018
      Registration statement for certain foreign private issuers offered for certain transactions
      Filing Type: F-3Filing Source: edgar
      Filing Date: May, 15 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 03 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: April, 13 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 11 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 27 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 26 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: SMMT)

      Daily Technical Chart for (NASDAQ: SMMT)


      Stay tuned for daily updates and more on (NASDAQ: SMMT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: SMMT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SMMT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SMMT and does not buy, sell, or trade any shares of SMMT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/